Lumos Pharma, Inc. (LUMO) Tops Q3 EPS by 11c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q3 EPS of ($1.04), $0.11 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $7 thousand versus the consensus estimate of $225.4 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• CoStar Group acquires Zonda for $800M, adding new home data
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group